Abstract
With the support of the Swedish National Institute of Health a national information service was started in 1993 aiming to capture the abuse of doping agents in the general public. It was organized as a telephone service, called the Anti-Doping Hot-Line, from our department and managed by trained nurses co-operating with clinical pharmacologists. Important information collected about all callers (anonymous) was: date of call, its origin, category of caller, doping experience and main question being asked. Abusers were asked about their age, sex, affiliation, abused drug(s), duration of abuse, habit of administration and adverse reactions (ADRs). Between October 1993 and December 2000 25,835 calls were received with a peak during spring and autumn. Most calls (12,400) came from non-abusers, 60% being males. Callers connected with gyms represented the largest group (30%). Most calls about specific drugs concerned anabolic androgenic steroids (AAS). Other drugs or products included ephedrine, clenbuterol and creatine. The most commonly abused anabolic steroids were testosterone, nandrolone-decanoate, methandienone and stanozolol. The ten most commonly reported ADRs of AAS were aggressiveness (835), depression (829), acne (770), gynecomastia (637), anxiousness (637), potency problems (413), testicular atrophy (404), sleep disorders (328), fluid retention (318) and mood disturbances (302). Female side effects included menstruation disturbances, hair growth in the face, lower voice and enlarged clitoris. During the period 1996–200, totally 4339 persons reported about 10,800 side effects. This figure should be compared with the very low number of ADRs (27) reported by prescribers to the Swedish ADR committee during the same period. Abuse of doping agents appears to be a new public health problem that needs detection, medical care and prevention.
Similar content being viewed by others
References
Ljungqvist A, Björkhem I, Eriksson B, Sjöqvist F, Elwin CE, Ek H, Lantto O, Garle M, Krievins S (1982) Doping—ett medicinskt och etiskt problem. Läkartidningen 79:1237–1249
Byqvist S (2002) Reports numbers 44 and 45 about trends in abuse of alcohol and drugs. Central agency for information about alcohol and narcotics (CAN), Stockholm
Hermansson G, Kröjs P (2001) Facts about doping agencies. A Swedish customs report 2001
Sturmi JE, Diorio DJ (1998) Anabolic agents. Clin Sports Med 17:261–282
Bahrke MS, Yesalis CE, Kopstein AN, Stephens JA (2000) Risk factors associated with anabolic–androgenic steroids use among adolescents. Sports Med 29:379–405
Scott MJ Jr (1996) Linear keloids resulting from abuse of anabolic androgenic steroid drugs. N Engl J Med 53:41–43
Björkqvist K, Nygren T, Björklund A-C, Björkqvist S-E (1994) Testosterone intake and aggressiveness: real effect or anticipation? Aggressive Behav 20:17–26
Thiblin I (1999) Anabolic androgenic steroids and violence. A medicolegal and experimental study. Thesis, Karolinska Institutet
Galliani N, Reneck A, Hansen S (1996) Personality profile of men using anabolic androgenic steroids. Horm Behav 30:170–175
Yeaslis CE, Herric RT, Buckley WE (1988) Self reported use of anabolic–androgenic steroids by elite power lifters. Physicians Sports Med 16:91–99
Kindlund AMS, Hagerkull B, Isacsson DG, Nyberg F (2001) Adolescent use of anabolic–androgenic steroids and relations to self reports of social, personality and health aspects. Eur J Public Health 11:322–328
Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow R (1993) Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 269:2760–2764
Acknowledgements
The following nurses/persons have served in the early years of the Anti-Doping Hot-Line and are gratefully acknowledged for their pioneering contributions: Christel Beckman, Jens Börjesson, Ulf Norberg, Kicki Stenback and Lars Ståhle.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eklöf, AC., Thurelius, AM., Garle, M. et al. The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol 59, 571–577 (2003). https://doi.org/10.1007/s00228-003-0633-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0633-z